Our partners
Gyala Therapeutics collaborates with leading clinical and academic institutions to support the development of our CAR-T therapy program, GYA01.
Hospital Clínic Barcelona and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) are internationally recognized clinical and research institutions with extensive expertise in academic CAR-T cell therapy development. Their achievements include the development of ARI-0001 (varnimcabtagene autoleucel) for adult relapsed or refractory acute lymphoblastic leukemia and ARI-0002h, a humanized BCMA-targeted CAR-T for multiple myeloma, both authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS). ARI-0001 has also been granted PRIME designation by the European Medicines Agency.
Dr. Manel Juan, Head of the Immunology Service at Hospital Clínic and leader of the IDIBAPS research group on Immunogenetics and Immunotherapy, played a central role in the scientific foundation and early development of Gyala Therapeutics and continues to collaborate closely with the company on research activities.
Hospital Clínic de Barcelona is a participating site in Gyala’s Phase I/IIa clinical trial, led by Principal Investigator Dr. Jordi Esteve.
The Health Research Institute Hospital La Fe (IIS La Fe) is a leading biomedical research center affiliated with Hospital La Fe.
Hospital La Fe is a participating site in Gyala’s Phase I/IIa clinical trial, led by Principal Investigator Dr. Pau Montesinos of the Hematology and Hemotherapy Research Group, an internationally recognized team with expertise in acute leukemia.
As part of a collaboration with Gyala Therapeutics and Hospital Clínic Barcelona led by Dr. Manuel Guerreiro, IIS La Fe is also responsible for the manufacture of GYA01 for patients treated at Hospital La Fe within Gyala’s Phase I/IIa clinical trial.